louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05726578: Integrated Echocardiography and Chest Ultrasound Assessment of Lung Recruitment in Preterm Infants
Official title: Integrated Echocardiography and Chest Ultrasound Assessment of Lung Recruitment in Preterm Infants Using High Frequency Ventilation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ventilator Lung
Echocardiography
Chest Ultrasound
High Frequency Ventilation
Lung Recruitment
Keywords: Premature infants
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2023-02-14
Enrollment: 72
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary aim of this work is to evaluate the role of high frequency oscillatory ventilation (HFOV) in recruitment of lung in preterm newborns 32 to 37 weeks gestational age with moderate to severe respiratory distress. The secondary aim is to evaluate the role of chest ultrasound in monitoring of lung recruitment in comparison to routine chest x ray in those babies. Also cardiac hemodynamics will be assesed using functional echocardiography.


Eligibility criteria: Inclusion Criteria:

* Infants will be enrolled if they are 32 to 37 weeks of gestational age, have respiratory distress (RD) in the first 24 h of life, intubated and have invasive respiratory support using HFOV. Signs of RD are tachypnea (respiratory rate \> 60/min), grunting, nasal flaring, chest retraction, and need of oxygen supplementation or other respiratory support.

Exclusion Criteria:

1. Known major congenital anomalies including congenital heart diseases.
2. Fetal hydrops.
3. Babies with congenital heart diseases

Primary outcomes:
measure: chest US
timeFrame: first 3 days after birth
measure: Superior Vena Cava flow in ml/kg/min
timeFrame: first 3 days of life
measure: estimated pulmonary artery pressure in mmHg
timeFrame: first 3 days of life
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Marwa Mohamed Farag
city: Alexandria
country: Egypt
facility: Neonatal Intensive Care Unit (NICU) of Alexandria University Maternity Hospital.
Study officials:
affiliation: Alexandria University
name: Mohamed Hazem Wagih Gouda, PhD
role: STUDY_CHAIR
affiliation: Alexandria University
name: Ali Mohamed Abd Almohsen, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05218278: NFL Dynamics as a Predictor Factor in Patients With Out of Hospital Cardiac Arrest
Official title: Dynamics of Light Chain of NFL as a Predictor Factor of Neurological Outcome in Patients With Out of Hospital Cardiac Arrest
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Out-Of-Hospital Cardiac Arrest
Neurological Injury
Lead sponsor: University Medical Centre Maribor
Sponsor class: OTHER
First posted: 2022-02-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with non-traumatic out-of-hospital cardiac arrest successfully resuscitated and admitted to the ICU.

Brief summary: To investigate the pharmacodynamics of light chain of NFL in patients with out-of hospital cardiac arrest after successful resuscitation and determine the difference in the serum levels of NFL in patients with favorable neurological outcome compared to those with non-favorable neurological outcome.

Detailed description: To investigate the serum levels of the light chain of NFL at different time points after ICU admission (12, 24, 30, 36, 42, 48 hours after ICU admission) patients with out-of hospital cardiac arrest after successful resuscitation and determine the difference in the serum levels of NFL in patients with favorable neurological outcome compared to those with non-favorable neurological outcome.

Eligibility criteria: Inclusion Criteria:

* out-of-hospital cardiac arrest successfully resuscitated and admitted to the ICU

Exclusion Criteria:

* trauma, drowning, electrocution, less than 18 years of age,

Primary outcomes:
measure: The difference in the dynamics of serum NFL levels measurements in patients with favorable neurological outcome compared to patients with non-favorable neurological outcome
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Maribor
country: Slovenia
facility: University medical center Maribor
Study officials:
affiliation: University medical cenetr Maribor
name: Matej Strnad, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01630278: Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
Official title: Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Patent Ductus Arteriosus
Keywords: Prematurity
patent ductus arteriosus
ibuprofen
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2012-06-28
Enrollment: 363
Sex: ALL
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Very premature infants with a large ductus, selected by an early echocardiogram, will receive either ibuprofen or placebo before 12 hours of life. Follow-up will include repeated echocardiograms and cranial ultrasound at 36 hours, 14 days and 36 weeks of postconceptional age. The primary outcome will be survival without cerebral palsy at years.


Eligibility criteria: Inclusion Criteria:

* Gestational less than 28 weeks
* Postnatal age less than 12 hours

Primary outcomes:
measure: 2-year survival without cerebral palsy
timeFrame: 2 years
Secondary outcomes:
measure: ASQ (Ages and Stages Questionnaire) score at 2 years
timeFrame: 2 years
measure: Incidence of other prematurity-related morbidities (pulmonary, digestive, neurological, renal)
timeFrame: 2 years
measure: Comparison of outcome according to the McNamara stage at surgical ligation
timeFrame: 2 years
Other outcomes:
Locations:
city: Angers
country: France
facility: University Hopsital
city: Bordeaux
country: France
facility: University Hopsital
city: Créteil
country: France
facility: University Hospital
city: Grenoble
country: France
facility: University Hospital
city: Lille
country: France
facility: University Hospital
city: Marseille
country: France
facility: University Hospital
city: Montpellier
country: France
facility: Univesity Hospital
city: Nantes
country: France
facility: University Hospital
city: Paris
country: France
facility: University Hospital (AP-HP Groupe hospitalier)
city: Rennes
country: France
facility: University Hospital
city: Tours
country: France
facility: University Hospital
Study officials:
affiliation: Nantes University Hospital
name: Jean-Christophe ROZE, Professor
role: STUDY_CHAIR
References:
citation: Roze JC, Cambonie G, Le Thuaut A, Debillon T, Ligi I, Gascoin G, Patkai J, Beuchee A, Favrais G, Flamant C, Durrmeyer X, Clyman R. Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. J Pediatr. 2021 Jun;233:33-42.e2. doi: 10.1016/j.jpeds.2020.12.008. Epub 2020 Dec 9.
citation: Mitra S, Scrivens A, von Kursell AM, Disher T. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev. 2020 Dec 10;12(12):CD013278. doi: 10.1002/14651858.CD013278.pub2.
Clinical trial NCT01810978: Synbiotics in Infants With Cyanotic Congenital Heart Disease
Official title: Efficacy of Synbiotics in Infants With Cyanotic Congenital Heart Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congenital Heart Disease
Keywords: congenital heart disease, probiotic, prebiotic
Lead sponsor: Dr. Sami Ulus Children's Hospital
Sponsor class: OTHER
First posted: 2013-03-14
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Infants with congenital heart disease have more frequent infections and exposures to antibiotics than healthy infants. The investigators hypothesized that synbiotics may reduce the rate of sepsis and necrotizing enterocolitis in infants with CHD

Detailed description: Infants with congenital heart disease have more frequent infections and exposures to antibiotics than healthy infants. Probiotics may prevent pathogen colonization in infants with CHD. Therefore, the investigators hypothesized that synbiotics may reduce the rate of sepsis and necrotizing enterocolitis in infants with CHD

Eligibility criteria: Inclusion Criteria:

* Cyanotic congenital heart disease
* infants \>35 weeks of gestational age
* Born at or transferred to Sami Ulus CH

Exclusion Criteria:

* Congenital anomalies of the intestinal tract

Primary outcomes:
measure: Sepsis
timeFrame: 8 weeks
Secondary outcomes:
measure: Necrotizing enterocolitis
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Sami Ulus CH
Study officials:
affiliation: MD
name: Banu Aydın, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ellis CL, Rutledge JC, Underwood MA. Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease. Gut Microbes. 2010 Nov-Dec;1(6):359-66. doi: 10.4161/gmic.1.6.14077.
citation: Dilli D, Aydin B, Zenciroglu A, Ozyazici E, Beken S, Okumus N. Treatment outcomes of infants with cyanotic congenital heart disease treated with synbiotics. Pediatrics. 2013 Oct;132(4):e932-8. doi: 10.1542/peds.2013-1262. Epub 2013 Sep 16.
Clinical trial NCT01817478: The Influence of Hospital Environment on Eyes Infections in Medical Staff
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Eye Infections
Keywords: conjunctival flora
Lead sponsor: Ziv Hospital
Sponsor class: OTHER_GOV
First posted: 2013-03-25
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The investigators want to find out if there is any difference between the microbiotic flora lining the conjunctiva of medical staff that work in the hospital and others who do not work in the hospital.


Eligibility criteria: Inclusion Criteria:

* healthy medical workers.

Exclusion Criteria:

* any ocular disease.
* previous ocular surgery.

Primary outcomes:
measure: significant difference in the bacterial flora of conjunctiva
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Safed
country: Israel
facility: Ziv Medical Center
Study officials:
References:
Clinical trial NCT01186978: Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
Official title: Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diffuse Large B-cell Lymphoma
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2010-08-23
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity.

Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET scan following rituximab-containing chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Histologic documentation of diffuse large B-cell lymphoma, or any of its variants as defined in the WHO classification
* Completion of at least 4 cycles of a rituximab-containing, anthracycline-based combination chemotherapy
* Negative post-chemotherapy (or interim) PET scan
* Absolute neutrophil count greater than 1500 and platelet count greater than 40,000
* Negative pregnancy test in women of child-bearing potential

For patients with HIV/AIDS, the following must be true:

* The patient is compliant on combination anti-retroviral therapy (CART)
* The patient has CD4 count ≥ 200 at time of diagnosis

Exclusion Criteria:

* Any contraindications to irradiation
* Primary CNS lymphoma
* HIV/AIDS

Primary outcomes:
measure: Number of Participants With Local Control
timeFrame: 5 years
Secondary outcomes:
measure: Percentage of Participants With Progression-free Survival at 5 Years
timeFrame: 5 years
measure: Percentage of Participants With Overall Survival
timeFrame: 5 years
measure: Number of Participants With Local, Distant, or Local+Distant Failure
timeFrame: 5 years
Other outcomes:
Locations:
city: Durham
country: United States
facility: Durham Regional Hospital
state: North Carolina
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Raleigh
country: United States
facility: Duke Raleigh Hospital
state: North Carolina
Study officials:
affiliation: Duke University Medical Center, Radiation Oncology
name: Christopher Kelsey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01622478: Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes
Official title: Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Radiologically Positive Axillary Lymph Nodes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: sentinel lymph node biopsy
neoadjuvant chemotherapy
breast cancer
locally advanced breast cancer
positive axillary lymph node
negative conversion
Lead sponsor: Gangnam Severance Hospital
Sponsor class: OTHER
First posted: 2012-06-19
Enrollment: 120
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Advanced breast cancer patients with node-positive proved in preoperative imaging study

Brief summary: Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and higher false negative rate. Further, the response of NAC can be different in each lymph nodes. It is doubtful whether SLNB can accurately predict axillary lymph node (ALN) status after NAC. The aim of this study to determine the identification rate, the false-negative rate, and the accuracy of SLNB after NAC for node positive breast cancer.


Eligibility criteria: Inclusion Criteria:

* Advanced breast cancer patients with node-positive proved in preoperative imaging study
* ECOG status 0-1

Exclusion Criteria:

* No previous cancer history
* No previous chemotherapy history

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital
Study officials:
References:
Clinical trial NCT03246178: Haploidentical Transplantation in Severe Aplastic Anemia
Official title: A Research on Haploidentical Transplantation in Severe Aplastic Anemia Using Reduced-intensity Fludarabine-based Conditioning
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Severe Aplastic Anemia
Keywords: Haploidentical
Hematopoietic stem cell transplantation
Severe aplastic anemia
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2017-08-11
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients with SAA
Primary purpose: TREATMENT

Brief summary: This is a prospective case-control study on SAA patients treated with HSCT, order to further discuss and assess the safety, feasibility and effectiveness of HFD-HSCT which performed with reduced-intensity fludarabine-based conditioning regimen.Our findings would indicate that SAA patients who lack MSD benefited most if HFD-HSCT was performed with reduced-intensity fludarabine-based conditioning regimen, and our improved outcomes with HFD-HSCT may lead to a salvaged therapy and an expanded direct role for SAA in the future.


Eligibility criteria: Inclusion Criteria:

(i) Diagnosis of SAA, very SAA or SAA and paroxysmal nocturnal hemoglobinuria (PNH) according to the International Aplastic Anemia Study Group; (ii) SAA patients no response to previous IST; (iii) adequate performance status \[Eastern Cooperative Oncology Group (ECOG) score 0-2\].

Exclusion Criteria:

(i) Congenital forms of aplastic anemia; (ii)Patients with any severe pulmonary, cardiac, liver, or renal diseases or active infection.

Primary outcomes:
measure: Engraftment
timeFrame: In the first months after infusion
measure: Toxicity grading
timeFrame: TRT was defined as toxic effects occurring within 40 days after HSCT
measure: Chimerism analyses +30
timeFrame: Days +30 after HSCT
measure: Chimerism analyses +100
timeFrame: Days +100 after HSCT
measure: Chimerism analyses +180
timeFrame: Days +180 after HSCT
measure: Chimerism analyses +365
timeFrame: Days +365 after HSCT
measure: OS 1-year
timeFrame: 1-year after HSCT
measure: OS 2-year
timeFrame: 2-year after HSCT
measure: OS 5-year
timeFrame: 5-year after HSCT
measure: EFS 1-year
timeFrame: 1-year after HSCT
measure: EFS 2-year
timeFrame: 2-year after HSCT
measure: EFS 5-year
timeFrame: 5-year after HSCT
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Hematology, 304th Clinical Division, Chinese PLA General Hospital
Study officials:
affiliation: The First Affiliated Hospital of General Hospital of PLA
name: Xiaoxiong WU, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02818478: Patient Reported Outcomes Reported Via PC / Tablet Home Versus Touch Screen at Hospital Among Patients With Arthritis
Official title: Patient Reported Outcome Measures Reported Into the Danish Arthritis Registry (DANBIO) Via Computer or Tablet at Home Versus Touch Screen at the Outpatient Clinic Among Patients With Axial Spondyloarthritis or Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rheumatoid Arthritis
Axial Spondyloarthritis
Lead sponsor: Parker Research Institute
Sponsor class: OTHER
Collaborators: name: The DANBIO registry, Denmark
name: Rigshospitalet, Denmark
First posted: 2016-06-29
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To investigate if electronic reporting of patient reported outcome measures from home is comparable to the traditional touch-screen solution to hospital among patients with rheumatoid arthritis and axial spondyloarthritis


Eligibility criteria: Inclusion Criteria

* Rheumatoid arthirtis OR axial spondyloarthritis
* Active treatment and monitoring of the Knowledge Center for Rheumatology and Spine diseases, Rigshospitalet, Denmark
* Patients must have reported patient reported outcome measures via DANBIOs touch-screen solution ≥ 3 times

Exclusion Criteria

* Impaired vision
* Non-Danish speaking
* No electronic device at home,, tablet or computer

Primary outcomes:
measure: HAQ
timeFrame: 48 hours
Secondary outcomes:
measure: 100 mm VAS global
timeFrame: 48 hours
measure: 100 mm VAS pain
timeFrame: 48 hours
measure: 100 mm VAS fatigue
timeFrame: 48 hours
measure: BASDAI
timeFrame: 48 hours
measure: BASFI
timeFrame: 48 hours
measure: BASDAI 5 & 6
timeFrame: 48 hours
Other outcomes:
measure: Smoking questionnaire
timeFrame: 48 hours
measure: Alcohol consumption (units consumed per week)
timeFrame: 48 hours
measure: Exercise questionnaire
timeFrame: 48 hours
measure: Medical conditions questionnaire
timeFrame: 48 hours
Locations:
Study officials:
affiliation: Rigshospitalet, Denmark
name: Merete M Hetland, MD.PhD.DMSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05764278: The Efficacy and Safety of Early Rehabilitation in Large Vessel Occlusion Patients After Intra-arterial Thrombectomy: A Prospective Randomized Controlled Trial
Official title: Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Intra-arterial Thrombectomy
Lead sponsor: National Taiwan University Hospital Hsin-Chu Branch
Sponsor class: OTHER
First posted: 2023-03-10
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Early rehabilitation is feasible for stroke patients is still under debate. In addition, IA thrombectomy has been a new treatment for the past few years and currently no known research exploring the efficacy of very early rehabilitation after thrombectomy, or any possible rehabilitation-related adverse effects. Therefore, in this study, the investigators will investigate the effectiveness of earlier rehabilitation intervention after IA thrombectomy for cerebral large vessel occlusion based on functional independence.

Detailed description: The study will be the prospective randomized controlled trial, where patients eligible for inclusion will be randomly assigned to earlier rehabilitation group or control group. The investigators will analyze the correlation between frequency/intensity of rehabilitation and primary/secondary outcomes. Dose-response analysis for earlier rehabilitation will be performed.

Eligibility criteria: Inclusion Criteria:

1. Cerebral stroke due to infarction of large vessels in the anterior circulation, including internal carotid artery (, middle cerebral artery (MCA) M1 or M2 segment, anterior cerebral artery (ACA) A1 segment
2. Receive arterial thrombectomy (IA thrombectomy)
3. Stable vital signs include heartbeat less than 130 bpm, systolic blood pressure less than 180mmHg, blood oxygen SpO2 \>92%
4. No use of pressors, oxygen masks or respirators after arterial thrombectomy

Exclusion Criteria:

1. Posterior circulation large vessel stroke
2. Functional score (mRS) ≥ 3 points before the stroke
3. Other contraindications for rehabilitation treatment
4. Neurosurgery immediately after this stroke
5. Those who cannot receive rehabilitation within one week of stroke due to serious medical problems
6. After the stroke, two specialists judged the end of life and arranged palliative and palliative treatment

Primary outcomes:
measure: Modified Rankin Scale (mRS)
timeFrame: 3rd months after stroke
Secondary outcomes:
measure: Barthel Index
timeFrame: 1st and 3rd months after stroke
measure: Modified Rankin Scale (mRS)
timeFrame: 1st months after stroke
measure: Fugl-Meyer Assessment
timeFrame: 1st and 3rd month after stroke
Other outcomes:
Locations:
city: Hsinchu
country: Taiwan
facility: National Taiwan University Hospital Hsin-Chu Branch Hsinchu, Taiwan
Study officials:
References: